123 related articles for article (PubMed ID: 37806829)
1. Impact of primary tumor resection and metastasectomy among gastroentero-pancreatic neuroendocrine tumors with liver metastases only on survival.
Chen Q; Li K; Rhodin KE; Bartholomew AJ; Lidsky ME; Wei Q; Cai J; Luo S; Zhao H
HPB (Oxford); 2024 Jan; 26(1):125-136. PubMed ID: 37806829
[TBL] [Abstract][Full Text] [Related]
2. Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: A SEER-based analysis.
Zheng M; Li Y; Li T; Zhang L; Zhou L
Cancer Med; 2019 Sep; 8(11):5128-5136. PubMed ID: 31328428
[TBL] [Abstract][Full Text] [Related]
3. Primary tumor resection improves survival of gastrointestinal neuroendocrine carcinoma patients with nonresected liver metastases.
Chen Q; Li K; Rhodin KE; Masoud SJ; Lidsky ME; Cai J; Wei Q; Luo S; Zhao H
J Surg Oncol; 2023 May; 127(6):945-955. PubMed ID: 36807890
[TBL] [Abstract][Full Text] [Related]
4. Resection of Primary Gastrointestinal Neuroendocrine Tumor Among Patients with Non-Resected Metastases Is Associated with Improved Survival: A SEER-Medicare Analysis.
Tsilimigras DI; Hyer JM; Paredes AZ; Ejaz A; Cloyd JM; Beane JD; Dillhoff M; Tsung A; Pawlik TM
J Gastrointest Surg; 2021 Sep; 25(9):2368-2376. PubMed ID: 33403563
[TBL] [Abstract][Full Text] [Related]
5. Resection of the Primary Gastrointestinal Neuroendocrine Tumor Improves Survival With or Without Liver Treatment.
Lewis A; Raoof M; Ituarte PHG; Williams J; Melstrom L; Li D; Lee B; Singh G
Ann Surg; 2019 Dec; 270(6):1131-1137. PubMed ID: 29746336
[TBL] [Abstract][Full Text] [Related]
6. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection.
Lv Y; Han X; Xu XF; Ji Y; Zhou YH; Sun HC; Zhou J; Fan J; Lou WH; Huang C
BMC Cancer; 2019 Apr; 19(1):335. PubMed ID: 30961559
[TBL] [Abstract][Full Text] [Related]
7. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
[TBL] [Abstract][Full Text] [Related]
8. Resection of the primary tumor improves the prognosis of gastrointestinal neuroendocrine neoplasms with liver metastases: mutual validation based on SEER database and institutional data.
Liu Y; Wang Z; Lin Q; Cui R; Tang W; Li G; Wang Z
BMC Gastroenterol; 2023 Nov; 23(1):408. PubMed ID: 37993767
[TBL] [Abstract][Full Text] [Related]
9. Resection of the Primary Tumor Improves the Survival of Patients With Stage IV Gastric Neuroendocrine Carcinoma.
Li Z; Ren H; Wang T; Zhang X; Zhao L; Sun C; Niu P; Guo C; Chen Y; Zhao D
Front Oncol; 2022; 12():930491. PubMed ID: 35912176
[TBL] [Abstract][Full Text] [Related]
10. Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: Comparison of gastro-enteric and pancreatic locations.
Russolillo N; Vigano' L; Razzore P; Langella S; Motta M; Bertuzzo F; Papotti M; Ferrero A
Eur J Surg Oncol; 2015 Jun; 41(6):751-7. PubMed ID: 25887286
[TBL] [Abstract][Full Text] [Related]
11. Aggressive Locoregional Treatment Improves the Outcome of Liver Metastases from Grade 3 Gastroenteropancreatic Neuroendocrine Tumors.
Du S; Ni J; Weng L; Ma F; Li S; Wang W; Sang X; Lu X; Zhong S; Mao Y
Medicine (Baltimore); 2015 Aug; 94(34):e1429. PubMed ID: 26313798
[TBL] [Abstract][Full Text] [Related]
12. Primary tumor resection and lymph node dissection improve survival in
Wu C; Zhang X; Wang T; Zhou H; Guo C; Chen Y; Zhao D
Transl Cancer Res; 2020 May; 9(5):3312-3323. PubMed ID: 35117698
[TBL] [Abstract][Full Text] [Related]
13. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas.
Galleberg RB; Knigge U; Tiensuu Janson E; Vestermark LW; Haugvik SP; Ladekarl M; Langer SW; Grønbæk H; Österlund P; Hjortland GO; Assmus J; Tang L; Perren A; Sorbye H
Eur J Surg Oncol; 2017 Sep; 43(9):1682-1689. PubMed ID: 28522174
[TBL] [Abstract][Full Text] [Related]
14. The Role of Primary Tumor Resection in Patients With Pancreatic Neuroendocrine Tumors With Liver Metastases.
Mou Y; Wang ZY; Tan CL; Chen YH; Liu XB; Ke NW
Front Oncol; 2022; 12():838103. PubMed ID: 35350567
[TBL] [Abstract][Full Text] [Related]
15. Is primary tumor resection associated with a longer survival in colon cancer and unresectable synchronous metastases? A 4-year multicentre experience.
de Mestier L; Neuzillet C; Pozet A; Desot E; Deguelte-Lardière S; Volet J; Karoui M; Kianmanesh R; Bonnetain F; Bouché O
Eur J Surg Oncol; 2014 Jun; 40(6):685-91. PubMed ID: 24630774
[TBL] [Abstract][Full Text] [Related]
16. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States.
Xu Z; Wang L; Dai S; Chen M; Li F; Sun J; Luo F
JAMA Netw Open; 2021 Sep; 4(9):e2124750. PubMed ID: 34554237
[TBL] [Abstract][Full Text] [Related]
17. Metastatic neuroendocrine tumors of the gastrointestinal tract and pancreas: A surgeon's plea to centering attention on the liver.
Keutgen XM; Schadde E; Pommier RF; Halfdanarson TR; Howe JR; Kebebew E
Semin Oncol; 2018 Aug; 45(4):232-235. PubMed ID: 30318110
[TBL] [Abstract][Full Text] [Related]
18. What have we learnt from the past - would treatment decisions for GEP-NET patients differ between 2012 to 2016 by the new recommendations in 2022?
Stiefel R; Lehmann K; Winder T; Siebenhüner AR
BMC Cancer; 2023 Feb; 23(1):148. PubMed ID: 36782152
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Primary Tumor Resection on Survival in Asymptomatic Colorectal Cancer Patients With Unresectable Metastases.
Doah KY; Shin US; Jeon BH; Cho SS; Moon SM
Ann Coloproctol; 2021 Apr; 37(2):94-100. PubMed ID: 33979907
[TBL] [Abstract][Full Text] [Related]
20. Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant
Parghane RV; Bhandare M; Chaudhari V; Ostwal V; Ramaswamy A; Talole S; Shrikhande SV; Basu S
J Nucl Med; 2021 Nov; 62(11):1558-1563. PubMed ID: 33637590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
